{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:23:25Z","timestamp":1760300605320,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00262-021-02952-1","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T15:25:49Z","timestamp":1622561149000},"page":"177-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["STAT3 is over-activated within CD163pos bone marrow macrophages in both Multiple Myeloma and the benign pre-condition MGUS"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0820-7789","authenticated-orcid":false,"given":"Morten N.","family":"Andersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels F.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina L.","family":"Lauridsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Etzerodt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boe S.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trine","family":"Plesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Hokland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger J.","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"2952_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"2952_CR2","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM et al (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412\u20135417. https:\/\/doi.org\/10.1182\/blood-2008-12-194241","journal-title":"Blood"},{"key":"2952_CR3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/leu.2008.203","volume":"22","author":"J Blad\u00e9","year":"2008","unstructured":"Blad\u00e9 J, Rosinol L, Cibeira MT, de Larrea CF (2008) Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 22:1651\u20131657. https:\/\/doi.org\/10.1038\/leu.2008.203","journal-title":"Leukemia"},{"key":"2952_CR4","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/leu.2014.59","volume":"28","author":"S Zhao","year":"2014","unstructured":"Zhao S, Choi M, Heuck C et al (2014) Serial exome analysis of disease progression in premalignant gammopathies. Leukemia 28:1548\u20131552. https:\/\/doi.org\/10.1038\/leu.2014.59","journal-title":"Leukemia"},{"key":"2952_CR5","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","volume":"128","author":"MV Dhodapkar","year":"2016","unstructured":"Dhodapkar MV (2016) MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 128:2599\u20132606. https:\/\/doi.org\/10.1182\/blood-2016-09-692954","journal-title":"Blood"},{"key":"2952_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","volume":"15","author":"IM Ghobrial","year":"2018","unstructured":"Ghobrial IM, Detappe A, Anderson KC, Steensma DP (2018) The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat Rev Clin Oncol 15:219\u2013233. https:\/\/doi.org\/10.1038\/nrclinonc.2017.197","journal-title":"Nat Rev Clin Oncol"},{"key":"2952_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/leu.2008.259","volume":"23","author":"K Podar","year":"2008","unstructured":"Podar K, Chauhan D, Anderson KC (2008) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23:10\u201324. https:\/\/doi.org\/10.1038\/leu.2008.259","journal-title":"Leukemia"},{"key":"2952_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050946","author":"Q-W Zhang","year":"2012","unstructured":"Zhang Q-W, Liu L, Gong C-Y et al (2012) Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0050946","journal-title":"PLoS ONE"},{"key":"2952_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cas.12314","volume":"105","author":"Y Komohara","year":"2014","unstructured":"Komohara Y, Jinushi M, Takeya M (2014) Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 105:1\u20138. https:\/\/doi.org\/10.1111\/cas.12314","journal-title":"Cancer Sci"},{"key":"2952_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"B-Z Qian","year":"2010","unstructured":"Qian B-Z, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39\u201351. https:\/\/doi.org\/10.1016\/j.cell.2010.03.014","journal-title":"Cell"},{"key":"2952_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW (2014) Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity 41:49\u201361. https:\/\/doi.org\/10.1016\/j.immuni.2014.06.010","journal-title":"Immunity"},{"key":"2952_CR12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.addr.2015.11.009","volume":"99","author":"Y Komohara","year":"2016","unstructured":"Komohara Y, Fujiwara Y, Ohnishi K, Takeya M (2016) Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev 99:180\u2013185. https:\/\/doi.org\/10.1016\/j.addr.2015.11.009","journal-title":"Adv Drug Deliv Rev"},{"key":"2952_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11:889\u2013896. https:\/\/doi.org\/10.1038\/ni.1937","journal-title":"Nat Immunol"},{"key":"2952_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature12034","volume":"496","author":"TA Wynn","year":"2013","unstructured":"Wynn TA, Chawla A, Pollard JW (2013) Macrophage biology in development, homeostasis and disease. Nature 496:445\u2013455. https:\/\/doi.org\/10.1038\/nature12034","journal-title":"Nature"},{"key":"2952_CR15","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1038\/s41467-018-05346-7","volume":"9","author":"T Muliaditan","year":"2018","unstructured":"Muliaditan T, Caron J, Okesola M et al (2018) Macrophages are exploited from an innate wound healing response to facilitate cancer metastasis. Nat Commun 9:2951. https:\/\/doi.org\/10.1038\/s41467-018-05346-7","journal-title":"Nat Commun"},{"key":"2952_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00277-012-1652-6","volume":"92","author":"E Suyan\u0131","year":"2013","unstructured":"Suyan\u0131 E, Sucak GT, Aky\u00fcrek N et al (2013) Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol 92:669\u2013677. https:\/\/doi.org\/10.1007\/s00277-012-1652-6","journal-title":"Ann Hematol"},{"key":"2952_CR17","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/leu.2015.191","volume":"30","author":"S Panchabhai","year":"2016","unstructured":"Panchabhai S, Kelemen K, Ahmann G et al (2016) Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma. Leukemia 30:951\u2013954. https:\/\/doi.org\/10.1038\/leu.2015.191","journal-title":"Leukemia"},{"key":"2952_CR18","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.7150\/jca.30102","volume":"10","author":"H Wang","year":"2019","unstructured":"Wang H, Hu W-M, Xia Z-J et al (2019) High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens. J Cancer 10:3239\u20133245. https:\/\/doi.org\/10.7150\/jca.30102","journal-title":"J Cancer"},{"key":"2952_CR19","doi-asserted-by":"publisher","first-page":"112685","DOI":"10.18632\/oncotarget.22340","volume":"8","author":"X Chen","year":"2017","unstructured":"Chen X, Chen J, Zhang W et al (2017) Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma. Oncotarget 8:112685\u2013112696. https:\/\/doi.org\/10.18632\/oncotarget.22340","journal-title":"Oncotarget"},{"key":"2952_CR20","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","volume":"114","author":"Y Zheng","year":"2009","unstructured":"Zheng Y, Cai Z, Wang S et al (2009) Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114:3625\u20133628. https:\/\/doi.org\/10.1182\/blood-2009-05-220285","journal-title":"Blood"},{"key":"2952_CR21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/leu.2012.272","volume":"27","author":"Y Zheng","year":"2012","unstructured":"Zheng Y, Yang J, Qian J et al (2012) PSGL-1\/selectin and ICAM-1\/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 27:702\u2013710. https:\/\/doi.org\/10.1038\/leu.2012.272","journal-title":"Leukemia"},{"key":"2952_CR22","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798\u2013809. https:\/\/doi.org\/10.1038\/nrc2734","journal-title":"Nat Rev Cancer"},{"key":"2952_CR23","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/1078-0432.CCR-16-0133","volume":"23","author":"DF Quail","year":"2017","unstructured":"Quail DF, Joyce JA (2017) Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies. Clin Cancer Res 23:876\u2013884. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0133","journal-title":"Clin Cancer Res"},{"key":"2952_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ejh.12296","volume":"93","author":"MN Andersen","year":"2014","unstructured":"Andersen MN, Abildgaard N, Maniecki MB et al (2014) Monocyte\/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma. Eur J Haematol 93:41\u201347. https:\/\/doi.org\/10.1111\/ejh.12296","journal-title":"Eur J Haematol"},{"key":"2952_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.leukres.2015.06.003","volume":"39","author":"MN Andersen","year":"2015","unstructured":"Andersen MN, Andersen NF, R\u00f8dgaard-Hansen S et al (2015) The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR\/sCD206): Implications in multiple myeloma. Leuk Res 39:971\u2013975. https:\/\/doi.org\/10.1016\/j.leukres.2015.06.003","journal-title":"Leuk Res"},{"key":"2952_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2249.2005.02934.x","volume":"142","author":"F Porcheray","year":"2005","unstructured":"Porcheray F, Viaud S, Rimaniol A-C et al (2005) Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 142:481\u2013489. https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02934.x","journal-title":"Clin Exp Immunol"},{"key":"2952_CR27","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20080108","volume":"205","author":"T Hagemann","year":"2008","unstructured":"Hagemann T, Lawrence T, McNeish I et al (2008) \u201cRe-educating\u201d tumor-associated macrophages by targeting NF- B. J Exp Med 205:1261\u20131268. https:\/\/doi.org\/10.1084\/jem.20080108","journal-title":"J Exp Med"},{"key":"2952_CR28","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/leu.2012.141","volume":"26","author":"D Kim","year":"2012","unstructured":"Kim D, Wang J, Willingham SB et al (2012) Anti-CD47 antibodies promote phagocytosis and inhibit thegrowth of human myeloma cells. Leukemia 26:2538\u20132545. https:\/\/doi.org\/10.1038\/leu.2012.141","journal-title":"Leukemia"},{"key":"2952_CR29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1158\/2326-6066.CIR-15-0025-T","volume":"3","author":"JL Jensen","year":"2015","unstructured":"Jensen JL, Rakhmilevich A, Heninger E et al (2015) Tumoricidal effects of macrophage-activating immunotherapy in a murine model of relapsed\/refractory multiple myeloma. Cancer Immunol Res 3:881\u2013890. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0025-T","journal-title":"Cancer Immunol Res"},{"key":"2952_CR30","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1182\/blood-2016-01-695395","volume":"128","author":"A Guti\u00e9rrez-Gonz\u00e1lez","year":"2016","unstructured":"Guti\u00e9rrez-Gonz\u00e1lez A, Mart\u00ednez-Moreno M, Samaniego R et al (2016) Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. Blood 128:2241\u20132252. https:\/\/doi.org\/10.1182\/blood-2016-01-695395","journal-title":"Blood"},{"key":"2952_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061803","author":"Y-L Su","year":"2018","unstructured":"Su Y-L, Banerjee S, White SV, Kortylewski M (2018) STAT3 in tumor-associated myeloid cells: multitasking to disrupt immunity. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19061803","journal-title":"Int J Mol Sci"},{"key":"2952_CR32","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu H, Lee H, Herrmann A et al (2014) Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14:736\u2013746. https:\/\/doi.org\/10.1038\/nrc3818","journal-title":"Nat Rev Cancer"},{"key":"2952_CR33","doi-asserted-by":"publisher","first-page":"7455","DOI":"10.1158\/0008-5472.CAN-10-0736","volume":"70","author":"A Herrmann","year":"2010","unstructured":"Herrmann A, Kortylewski M, Kujawski M et al (2010) Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res 70:7455\u20137464. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0736","journal-title":"Cancer Res"},{"key":"2952_CR34","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/gt.2015.70","volume":"22","author":"W Dang","year":"2015","unstructured":"Dang W, Tang H, Cao H et al (2015) Strategy of STAT3\u03b2 cell-specific expression in macrophages exhibits antitumor effects on mouse breast cancer. Gene Ther 22:977\u2013983. https:\/\/doi.org\/10.1038\/gt.2015.70","journal-title":"Gene Ther"},{"key":"2952_CR35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jconrel.2012.01.034","volume":"160","author":"A Etzerodt","year":"2012","unstructured":"Etzerodt A, Maniecki MB, Graversen JH et al (2012) Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J Control Release 160:72\u201380. https:\/\/doi.org\/10.1016\/j.jconrel.2012.01.034","journal-title":"J Control Release"},{"key":"2952_CR36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00262-019-02301-3","volume":"68","author":"MN Andersen","year":"2019","unstructured":"Andersen MN, Etzerodt A, Graversen JH et al (2019) STAT3 inhibition specifically in human monocytes and macrophages by CD163-targeted corosolic acid-containing liposomes. Cancer Immunol Immunother 68:489\u2013502. https:\/\/doi.org\/10.1007\/s00262-019-02301-3","journal-title":"Cancer Immunol Immunother"},{"key":"2952_CR37","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1186\/s40364-017-0106-7","volume":"216","author":"A Etzerodt","year":"2019","unstructured":"Etzerodt A, Tsalkitzi K, Maniecki M et al (2019) Specific targeting of CD163 +TAMs mobilizes inflammatory monocytes and promotes T cell\u2013mediated tumor regression. J Exp Med 216:2394\u20132411. https:\/\/doi.org\/10.1186\/s40364-017-0106-7","journal-title":"J Exp Med"},{"key":"2952_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/003655102760145852","volume":"62","author":"HJ M\u00f8ller","year":"2002","unstructured":"M\u00f8ller HJ, Hald K, Moestrup SK (2002) Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand J Clin Lab Invest 62:293\u2013299","journal-title":"Scand J Clin Lab Invest"},{"key":"2952_CR39","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1515\/cclm-2013-0451","volume":"52","author":"S R\u00f8dgaard-Hansen","year":"2014","unstructured":"R\u00f8dgaard-Hansen S, Rafique A, Christensen PA et al (2014) A soluble form of the macrophage-related mannose receptor (MR\/CD206) is present in human serum and elevated in critical illness. Clin Chem Lab Med 52:453\u2013461. https:\/\/doi.org\/10.1515\/cclm-2013-0451","journal-title":"Clin Chem Lab Med"},{"key":"2952_CR40","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1158\/0008-5472.CAN-04-0496","volume":"64","author":"CL Andersen","year":"2004","unstructured":"Andersen CL, Jensen JL, \u00d8rntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64:5245\u20135250. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0496","journal-title":"Cancer Res"},{"key":"2952_CR41","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/path.4860","volume":"241","author":"N De Beule","year":"2017","unstructured":"De Beule N, De Veirman K, Maes K et al (2017) Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation. J Pathol 241:534\u2013546. https:\/\/doi.org\/10.1002\/path.4860","journal-title":"J Pathol"},{"key":"2952_CR42","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3389\/fimmu.2017.01347","volume":"8","author":"A Bosseboeuf","year":"2017","unstructured":"Bosseboeuf A, Allain-Maillet S, Mennesson N et al (2017) Pro-inflammatory state in monoclonal gammopathy of undetermined significance and in multiple myeloma is characterized by low sialylation of pathogen-specific and other monoclonal immunoglobulins. Front Immunol 8:1347. https:\/\/doi.org\/10.3389\/fimmu.2017.01347","journal-title":"Front Immunol"},{"key":"2952_CR43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/ejh.13371","volume":"104","author":"SL Kvorning","year":"2020","unstructured":"Kvorning SL, Nielsen MC, Andersen NF et al (2020) Circulating extracellular vesicle-associated CD163 and CD206 in multiple myeloma. Eur J Haematol 104:409\u2013419. https:\/\/doi.org\/10.1111\/ejh.13371","journal-title":"Eur J Haematol"},{"key":"2952_CR44","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1002\/ijc.27506","volume":"131","author":"MB Maniecki","year":"2012","unstructured":"Maniecki MB, Etzerodt A, Ulh\u00f8i BP et al (2012) Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer 131:2320\u20132331. https:\/\/doi.org\/10.1002\/ijc.27506","journal-title":"Int J Cancer"},{"key":"2952_CR45","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/j.1349-7006.2010.01614.x","volume":"101","author":"H Hasita","year":"2010","unstructured":"Hasita H, Komohara Y, Okabe H et al (2010) Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 101:1913\u20131919. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01614.x","journal-title":"Cancer Sci"},{"key":"2952_CR46","doi-asserted-by":"publisher","first-page":"7847","DOI":"10.1038\/ncomms8847","volume":"6","author":"R Nakamura","year":"2015","unstructured":"Nakamura R, Sene A, Santeford A et al (2015) IL10-driven STAT3 signalling in senescent macrophages promotes pathological eye angiogenesis. Nat Commun 6:7847. https:\/\/doi.org\/10.1038\/ncomms8847","journal-title":"Nat Commun"},{"key":"2952_CR47","doi-asserted-by":"publisher","first-page":"43992","DOI":"10.18632\/oncotarget.6083","volume":"6","author":"J Wang","year":"2015","unstructured":"Wang J, De Veirman K, De Beule N et al (2015) The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. Oncotarget 6:43992\u201344004. https:\/\/doi.org\/10.18632\/oncotarget.6083","journal-title":"Oncotarget"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02952-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-02952-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02952-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T12:08:26Z","timestamp":1641470906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-02952-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2952"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-02952-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"assertion":[{"value":"24 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HJM is a minority shareholder in DeLiver Pharma that holds IP protecting the use of CD163 drug targeting. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}